Referências
Principais artigos
Dechet AM, Yu PA, Koram N, et al. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis. 2008;46:970-6. Resumo
California Department of Public Health. CDPH IDB guidance for managing select communicable diseases: non-cholera Vibrio infections. Jun 2023 [internet publication].Texto completo
Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-143.Texto completo Resumo
Centers for Disease Control and Prevention. Vibrio species causing vibriosis. Information for health professionals and laboratorians. Aug 2023 [internet publication].Texto completo
Artigos de referência
1. Kaysner CA, DePaola A, Jones J. Chapter 9: Vibrio. In: Bacteriological Analytical Manual. Silver Spring, MD: Food and Drug Administration; 2019.Texto completo
2. Integrated Taxonomic Information System (ITIS) online database [internet publication].Texto completo
3. Penland R, Boniuk M, Wilhelmus KR. Vibrio ocular infections on the U.S. Gulf Coast. Cornea. 2000;19:26-29. Resumo
4. Dechet AM, Yu PA, Koram N, et al. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis. 2008;46:970-6. Resumo
5. Trinanes J, Martinez-Urtaza J. Future scenarios of risk of Vibrio infections in a warming planet: a global mapping study. Lancet Planet Health. 2021 Jul;5(7):e426-e435.Texto completo Resumo
6. Centers for Disease Control and Prevention. Cholera and Other Vibrio Illness Surveillance (COVIS) system annual summary. Sep 2023 [internet publication].Texto completo
7. Food and Drug Administration. FDA investigated multistate outbreak of vibrio parahaemolyticus linked to fresh crab meat imported from Venezuela. Sep 2018 [internet publication].Texto completo
8. Centers for Disease Control and Prevention. Multistate outbreak of gastrointestinal illnesses linked to oysters imported from Mexico. Jun 2019 [internet publication].Texto completo
9. Sodders N, Stockdale K, Baker K, et al. Notes from the field: vibriosis cases associated with flood waters during and after hurricane Ian - Florida, September-October 2022. MMWR Morb Mortal Wkly Rep. 2023 May 5;72(18):497-98.Texto completo Resumo
10. Centers for Disease Control and Prevention. Severe Vibrio vulnificus infections in the United States associated with warming coastal waters. Sep 2023 [internet publication].Texto completo
11. Inoue Y, Ono T, Matsui T, et al. Epidemiological survey of Vibrio vulnificus infection in Japan between 1999 and 2003. J Dermatol. 2008;35:129-39. Resumo
12. Wootipoom N, Bhoopong P, Pomwised R, et al. A decrease in the proportion of infections by pandemic Vibrio parahaemolyticus in Hat Yai Hospital, southern Thailand. J Med Microbiol. 2007;56:1630-8.Texto completo Resumo
13. Khaira G, Galanis E. Descriptive epidemiology of Vibrio parahaemolyticus and other Vibrio species infections in British Columbia: 2001-2006. Can Commun Dis Rep. 2007;33:12-22.Texto completo Resumo
14. Public Health Agency of Canada. Public health notice: outbreak of Vibrio parahaemolyticus linked to raw shellfish. Oct 2015. http://www.phac-aspc.gc.ca/.Texto completo
15. Martinez-Urtaza J, Huapaya B, Gavilan RG, et al. Emergence of Asiatic Vibrio diseases in South America in phase with El Nino. Epidemiology. 2008;19:829-37. Resumo
16. Harth E, Matsuda L, Hernández C, et al. Epidemiology of Vibrio parahaemolyticus outbreaks, southern Chile. Emerg Infect Dis. 2009;15:163-8.Texto completo Resumo
17. California Department of Public Health. CDPH IDB guidance for managing select communicable diseases: non-cholera Vibrio infections. Jun 2023 [internet publication].Texto completo
18. Hsueh PR, Lin CY, Tang HJ, et al. Vibrio vulnificus in Taiwan. Emerg Infect Dis. 2004;10:1363-8.Texto completo Resumo
19. Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect. 2005;133:383-91. Resumo
20. Thompson FL, Gevers D, Thompson CC, et al. Phylogeny and molecular identification of vibrios on the basis of multilocus sequence analysis. Appl Environ Microbiol. 2005;71:5107-15.Texto completo Resumo
21. Thompson FL, Iida T, Swings J. Biodiversity of vibrios. Microbiol Mol Biol Rev. 2004;68:403-31.Texto completo Resumo
22. Chuang PY, Yang TY, Huang TW, et al. Hepatic disease and the risk of mortality of Vibrio vulnificus necrotizing skin and soft tissue infections: a systematic review and meta-analysis. PLoS One. 2019 Oct 25;14(10):e0223513.Texto completo Resumo
23. Yun NR, Kim DM. Vibrio vulnificus infection: a persistent threat to public health. Korean J Intern Med. 2018 Nov;33(6):1070-8.Texto completo Resumo
24. Schmidt U, Chmel H, Cobbs C. Vibrio alginolyticus infections in humans. J Clin Microbiol. 1979;10:666-8.Texto completo Resumo
25. Patterson TF, Bell SR, Bia FJ. Vibrio alginolyticus cellulitis following coral injury. Yale J Biol Med. 1988;61:507-12.Texto completo Resumo
26. Gomez JM, Fajardo R, Patino JF, et al. Necrotizing fasciitis due to Vibrio alginolyticus in an immunocompetent patient. J Clin Microbiol. 2003;41:3427-9.Texto completo Resumo
27. Opal SM, Saxon JR. Intracranial infection by Vibrio alginolyticus following injury in salt water. J Clin Microbiol. 1986;23:373-4.Texto completo Resumo
28. Strom MS, Paranjpye RN. Epidemiology and pathogenesis of Vibrio vulnificus. Microbes Infect. 2000;2:177-88. Resumo
29. Miyoshi S. Vibrio vulnificus infection and metalloprotease. J Dermatol. 2006;33:589-95. Resumo
30. Kim K, Kim NJ, Kim SY, et al. Cyclo(Phe-Pro) produced by the human pathogen Vibrio vulnificus inhibits host innate immune responses through the NF-κB pathway. Infect Immun. 2015;83:1150-61.Texto completo Resumo
31. Jang HC, Choi SM, Kim HK, et al. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis. PLoS One. 2014;9:e101118.Texto completo Resumo
32. Broberg CA, Calder TJ, Orth K. Vibrio parahaemolyticus cell biology and pathogenicity determinants. Microbes Infect. 2011;13:992-1001.Texto completo Resumo
33. Zhang L, Orth K. Virulence determinants for Vibrio parahaemolyticus infection. Curr Opin Microbiol. 2013;16:70-7. Resumo
34. de Souza Santos M, Orth K. Intracellular Vibrio parahaemolyticus escapes the vacuole and establishes a replicative niche in the cytosol of epithelial cells. MBio. 2014;5:e01506-14.Texto completo Resumo
35. Tantillo GM, Fontanarosa M, Di Pinto A, et al. Updated perspectives on emerging vibrios associated with human infections. Lett Appl Microbiol. 2004;39:117-26. Resumo
36. Kumamoto KS, Vukich DJ. Clinical infections of Vibrio vulnificus: a case report and review of the literature. J Emerg Med. 1998;16:61-6. Resumo
37. Janda JM, Powers C, Bryant RG, et al. Current perspectives on the epidemiology and pathogenesis of clinically significant Vibrio spp. Clin Microbiol Rev. 1988;1:245-67.Texto completo Resumo
38. Hor LI, Chang TT, Wang ST. Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J Infect Dis. 1999;179:275-8. Resumo
39. Hor LI, Chang YK, Chang CC, et al. Mechanism of high susceptibility of iron-overloaded mouse to Vibrio vulnificus infection. Microbiol Immunol. 2000;44:871-8. Resumo
40. Daniels NA. Vibrio vulnificus oysters: pearls and perils. Clin Infect Dis. 2011;52:788-92.Texto completo Resumo
41. Vugia DJ, Tabnak F, Newton AE, et al. Impact of 2003 state regulation on raw oyster-associated Vibrio vulnificus illnesses and deaths, California, USA. Emerg Infect Dis. 2013;19:1276-80.Texto completo Resumo
42. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-143.Texto completo Resumo
43. Dan T, Qin H, Sun C, et al. Detection of V. vulnificus septic shock with ARDS using mNGS. Open Life Sci. 2023;18(1):20220584.Texto completo Resumo
44. Scully EP, Earp BE, Miller AL, Loscalzo J. Just a cut. N Engl J Med. 2016;375:1780-6 Resumo
45. Centers for Disease Control and Prevention. Vibrio species causing vibriosis. Information for health professionals and laboratorians. Aug 2023 [internet publication].Texto completo
46. Baker-Austin C, Oliver JD, Alam M, et al. Vibrio spp. infections. Nat Rev Dis Primers. 2018 Jul 12;4(1):8.Texto completo Resumo
47. Marano NN, Daniels NA, Easton AN, et al. A survey of stool culturing practices for Vibrio species at clinical laboratories in Gulf Coast states. J Clin Microbiol. 2000 Jun;38(6):2267-70.Texto completo Resumo
48. Hedberg CW, Palazzi-Churas KL, Radke VJ, et al. The use of clinical profiles in the investigation of foodborne outbreaks in restaurants: United States, 1982-1997. Epidemiol Infect. 2008;136:65-72. Resumo
49. Liu JW, Lee IK, Tang HJ, et al. Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med. 2006;166:2117-23. [Erratum in: Arch Intern Med. 2007;167:194.]Texto completo Resumo
50. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304-77.Texto completo Resumo
51. Chao WN, Tsai CF, Chang HR, et al. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis. Am J Surg. 2013;206:32-9. Resumo
52. Daniels NA, MacKinnon L, Bishop R, et al. Vibrio parahaemolyticus infection in the United States, 1973-1998. J Infect Dis. 2000;181:1661-6. Resumo
53. Gilbert DN, Chambers HF, Saag MS, et al, eds. The Sanford guide to antimicrobial therapy 2023. 53rd ed. Sperryville, VA: Antimicrobial Therapy, Inc.; 2023.Texto completo
54. Kim SE, Shin SU, Oh TH, et al. Outcomes of third-generation cephalosporin plus ciprofloxacin or doxycycline therapy in patients with Vibrio vulnificus septicemia: a propensity score-matched analysis. PLoS Negl Trop Dis. 2019 Jun;13(6):e0007478.Texto completo Resumo
55. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. Nov 2018 [internet publication].Texto completo
56. Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Aug 2018 [internet publication].Texto completo
57. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Dec 2018 [internet publication].Texto completo
58. Food and Drug Administration. FDA Drug Safety Communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Jul 2018 [internet publication].Texto completo
59. Halow KD, Harner RC, Fontenelle LJ. Primary skin infections secondary to Vibrio vulnificus: the role of operative intervention. J Am Coll Surg. 1996;183:329-34. Resumo
60. Kuo YL, Shieh SJ, Chiu HY, et al. Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention. Eur J Clin Microbiol Infect Dis. 2007;26:785-92. Resumo
61. Huang KC, Hsieh PH, Huang KC, et al. Vibrio necrotizing soft-tissue infection of the upper extremity: factors predictive of amputation and death. J Infect. 2008;57:290-7. Resumo
62. Chen S, Chan K, Chao W, et al. Clinical outcomes and prognostic factors for patients with Vibrio vulnificus infections requiring intensive care: a 10 year retrospective study. Crit Care Med. 2010;38:1984-90. Resumo
63. Hong GL, Dai XQ, Lu CJ, et al. Temporizing surgical management improves outcome in patients with Vibrio necrotizing fasciitis complicated with septic shock on admission. Burns. 2014;40:446-54. Resumo
64. Chen SC, Lee YT, Tsai SJ, et al. Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus: retrospective analysis of an 8 year period. J Antimicrob Chemother. 2012;67:488-93.Texto completo Resumo
65. Tang H, Chen C, Lai C, et al. In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. J Microbiol Immunol Infect. 2018;51:76-81.Texto completo Resumo
66. Lin Y, Hung M, Chen C, et al. Tigecycline salvage therapy for necrotizing fasciitis caused by Vibrio vulnificus: case report in a child. J Microbiol Immunol Infect. 2016;49:138-41.Texto completo Resumo
67. Bell A, Bott M. Vibriosis: what you and your patients need to know. Dela J Public Health. 2021 Jan 21;7(1):14-21.Texto completo Resumo
68. Baker-Austin C, Oliver JD, Alam M, et al. Vibrio spp. infections. Nat Rev Dis Primers. 2018 Jul 12;4(1):8. [Erratum in: Nat Rev Dis Primers. 2021 Feb 19;7(1):15.]Texto completo Resumo
69. Chou TN, Lee YT, Lai YY, et al. Prognostic factors for primary septicemia and wound infection caused by Vibrio vulnificus. Am J Emerg Med. 2010;28:424-31. Resumo
70. Kuo SH, Tsai CF, Li CR, et al. Rapid Emergency Medicine Score as a main predictor of mortality in Vibrio vulnificus-related patients. Am J Emerg Med. 2013;31:1037-41. Resumo
71. Lee YC, Hor LI, Chiu HY, et al. Prognostic factor of mortality and its clinical implications in patients with necrotizing fasciitis caused by Vibrio vulnificus. Eur J Clin Microbiol Infect Dis. 2014;33:1011-8. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal